Abstracts tagged "treatment and uric acid"

Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Dinesh Khanna¹, Puja Khanna², Chris Storgard³, Scott Baumgartner⁴ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Scott Baumgartner¹, Hyon Choi^2,3, Nicola Dalbeth⁴, David Fitz-Patrick⁵, Matt Cravets⁶ and Chris Storgard⁷, ¹Ardea Biosciences, San Diego, CA, ²Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Auckland District Health Board, Auckland, New Zealand, ⁵East-West Medical Research Institute, Honolulu, HI, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷4939 Directors Place, Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…
Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Melea Ward¹, Anthony M. Louder², Keith A. Szymanski³ and Leonardo Tamariz⁴, ¹Competitive Health Analytics, Louisville, KY, ²Competitive Health Analytics, Inc., Louisville, KY, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL, ⁴University of Miami, Miami, FL
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].